Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study
Background - The aim of this subgroup analysis of the Mabthera International Trial Group study was to evaluate the impact of chemotherapy and rituximab in primary mediastinal B-cell lymphoma (PMBCL) in comparison to other diffuse large B-cell lymphoma (DLBCL). - Methods - Patients were randomly assi...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2011
|
| In: |
Annals of oncology
Year: 2011, Jahrgang: 22, Heft: 3, Pages: 664-670 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdq418 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/annonc/mdq418 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0923753419386156 
|
| Verfasserangaben: | M. Rieger, A. Österborg, R. Pettengell, D. White, D. Gill, J. Walewski, E. Kuhnt, M. Loeffler, M. Pfreundschuh & A.D. Ho, for the MabThera International Trial (MInT) Group |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1816727474 | ||
| 003 | DE-627 | ||
| 005 | 20230710114913.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220915s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdq418 |2 doi | |
| 035 | |a (DE-627)1816727474 | ||
| 035 | |a (DE-599)KXP1816727474 | ||
| 035 | |a (OCoLC)1389788594 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Rieger, Martin |e VerfasserIn |0 (DE-588)1268143332 |0 (DE-627)1816728136 |4 aut | |
| 245 | 1 | 0 | |a Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab |b results of the Mabthera International Trial Group study |c M. Rieger, A. Österborg, R. Pettengell, D. White, D. Gill, J. Walewski, E. Kuhnt, M. Loeffler, M. Pfreundschuh & A.D. Ho, for the MabThera International Trial (MInT) Group |
| 264 | 1 | |c 2011 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Elektronische Reproduktion der Druckausgabe | ||
| 500 | |a Gesehen am 15.09.2022 | ||
| 520 | |a Background - The aim of this subgroup analysis of the Mabthera International Trial Group study was to evaluate the impact of chemotherapy and rituximab in primary mediastinal B-cell lymphoma (PMBCL) in comparison to other diffuse large B-cell lymphoma (DLBCL). - Methods - Patients were randomly assigned to six cycles of CHOP-like regimens with or without rituximab. - Results - Of 824 patients enrolled, 87 had PMBCL and 627 other types of DLBCL. Rituximab increased the rates of complete remission (unconfirmed) in both PMBCL (from 54% to 80%, P = 0.015) and DLBCL (from 72% to 87%, P < 0.001). In PMBCL, rituximab virtually eliminated progressive disease (PD) (2.5% versus 24%, P < 0.001), whereas without rituximab, PD was more frequent in PMBCL than in DLBCL (24% versus 10%, P = 0.010). With a median observation time of 34 months, 3-year event-free survival (EFS) was improved by rituximab for PMBCL (78% versus 52%, P = 0.012) and for DLBCL (81% versus 61%, P < 0.001). Overall survival benefit was similar for DLBCL (93% versus 85%, P < 0.001) and PMBCL (89% versus 78%, P = 0.158). - Conclusion - In young patients with PMBCL (age-adjusted International Prognostic Index 0-1), rituximab added to six cycles of CHOP-like chemotherapy increases response rate and EFS to the same extent as other DLBCL. The combination of rituximab with CHOP chemotherapy is an effective treatment in PMBCL with good prognosis features. | ||
| 650 | 4 | |a MInT | |
| 650 | 4 | |a primary mediastinal B-cell lymphoma | |
| 650 | 4 | |a rituximab | |
| 700 | 1 | |a Österborg, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pettengell, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a White, D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gill, D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Walewski, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kuhnt, E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Loeffler, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pfreundschuh, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ho, Anthony Dick |d 1948- |e VerfasserIn |0 (DE-588)108692477 |0 (DE-627)504904205 |0 (DE-576)19010466X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 22(2011), 3, Seite 664-670 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab results of the Mabthera International Trial Group study |
| 773 | 1 | 8 | |g volume:22 |g year:2011 |g number:3 |g pages:664-670 |g extent:7 |a Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab results of the Mabthera International Trial Group study |
| 856 | 4 | 0 | |u https://doi.org/10.1093/annonc/mdq418 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0923753419386156 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220915 | ||
| 993 | |a Article | ||
| 994 | |a 2011 | ||
| 998 | |g 108692477 |a Ho, Anthony Dick |m 108692477:Ho, Anthony Dick |d 910000 |d 910100 |e 910000PH108692477 |e 910100PH108692477 |k 0/910000/ |k 1/910000/910100/ |p 7 | ||
| 999 | |a KXP-PPN1816727474 |e 4188864427 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["M. Rieger, A. Österborg, R. Pettengell, D. White, D. Gill, J. Walewski, E. Kuhnt, M. Loeffler, M. Pfreundschuh & A.D. Ho, for the MabThera International Trial (MInT) Group"]},"person":[{"family":"Rieger","display":"Rieger, Martin","given":"Martin","role":"aut"},{"given":"A.","role":"aut","display":"Österborg, A.","family":"Österborg"},{"display":"Pettengell, R.","given":"R.","role":"aut","family":"Pettengell"},{"family":"White","given":"D.","role":"aut","display":"White, D."},{"role":"aut","given":"D.","display":"Gill, D.","family":"Gill"},{"family":"Walewski","role":"aut","given":"J.","display":"Walewski, J."},{"display":"Kuhnt, E.","given":"E.","role":"aut","family":"Kuhnt"},{"display":"Loeffler, M.","role":"aut","given":"M.","family":"Loeffler"},{"given":"M.","role":"aut","display":"Pfreundschuh, M.","family":"Pfreundschuh"},{"given":"Anthony Dick","role":"aut","display":"Ho, Anthony Dick","family":"Ho"}],"origin":[{"dateIssuedDisp":"2011","dateIssuedKey":"2011"}],"recId":"1816727474","type":{"bibl":"article-journal","media":"Online-Ressource"},"relHost":[{"language":["eng"],"part":{"issue":"3","extent":"7","pages":"664-670","text":"22(2011), 3, Seite 664-670","year":"2011","volume":"22"},"title":[{"title_sort":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology","title":"Annals of oncology"}],"pubHistory":["1.1990 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford","dateIssuedKey":"1990","dateIssuedDisp":"1990-","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press"}],"recId":"320428796","corporate":[{"display":"European Society for Medical Oncology","role":"isb"}],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"disp":"Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab results of the Mabthera International Trial Group studyAnnals of oncology","physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1569-8041"],"zdb":["2003498-2"],"eki":["320428796"]}}],"note":["Elektronische Reproduktion der Druckausgabe","Gesehen am 15.09.2022"],"physDesc":[{"extent":"7 S."}],"id":{"doi":["10.1093/annonc/mdq418"],"eki":["1816727474"]},"language":["eng"],"title":[{"title":"Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab","subtitle":"results of the Mabthera International Trial Group study","title_sort":"Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab"}]} | ||
| SRT | |a RIEGERMARTPRIMARYMED2011 | ||